Clinical trials: Opioid-Use Disorder (OUD)
- Condition Opioid-Use Disorder (OUD)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Opioid Use Disorder
Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants
The purpose of this open label study is to characterise the absorption, metabolism, excretion, and mass balance of [14C]-IDV184001AN ([14C]-IDV184001) in healthy adult male participants.
- Trial name
- NCT05974046
- Testing
- [14C]IDV184001AN
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Opioid Use Disorder (OUD)
A Safety Study of AZD4041 in Healthy Participants
This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study in healthy male and female adult participants.
- Trial name
- NCT05233085
- Testing
- AZD4041
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Opioid-use Disorder, Contingency Management
Usability Testing for the Reward-based Technology to Improve OUD Treatment
Millions of people in the US misuse opioids each year, leading to thousands of deaths and costing billions of dollars in total economic burden.
- Conditions
- Opioid-use Disorder, Contingency Management, Medication for Opioid-use Disorder
- Trial name
- OARSCM (NCT05159362)
- Testing
- Software Application
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Q2i, LLC
Opioid Use Disorder
Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
- Trial name
- NCT05924945
- Testing
- Bridge™ active device
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masimo Corporation
Opioid Use Disorder
Reward-based Technology to Improve OUD Treatment
Millions of people in the US misuse opioids each year. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-adherence is common…
- Trial name
- OARSCM (NCT05180669)
- Testing
- OARSCM Software Application, MyMAT Software Application
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Q2i, LLC